BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women.

 

Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location.

 

With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. BCAL has partnered with Precion Inc. to optimise protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions, commercialisation and market entry points.

​

BCAL’s development and clinical service laboratory was officially opened in early May 2023. 

​

The laboratory is utilising the latest Liquid Chromatography Mass Spectrometry (LCMS) platforms to continue to advance the findings of the Company’s clinical research to-date and the progress made by BCAL Diagnostics’ US commercialisation partner, Precion Inc. to establish and validate workflows, test protocols and algorithms for the BCAL blood screening tool.  

 

The BCAL laboratory will also serve as a testing site for the ongoing and planned clinical validation studies and will establish a Quality Management System and protocols to be compliant to ISO 15189 and NPAAC standards, Clinical Laboratory Improvement Amendments (CLIA) regulations for Certification and the requirements of the Therapeutic Goods Act 1989 (Cth).

​

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX).

​